- Home
- BBTX vs NGNE Comparison
BBTX vs NGNE Comparison
Compare BBTX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBTX | NGNE |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.2M | 744.9M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BBTX | NGNE |
|---|---|---|
| Price | $16.95 | $26.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $77.88 |
| AVG Volume (30 Days) | N/A | ★ 327.3K |
| Earning Date | 12-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $15.93 |
| 52 Week High | N/A | $43.66 |
Technical Indicators
Market Signals| Indicator | BBTX | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.49 |
| Support Level | N/A | $24.88 |
| Resistance Level | N/A | $28.47 |
| Average True Range (ATR) | 0.00 | 2.60 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 0.00 | 29.95 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.